Diabetes mellitus (DM) ranks as the fourth cause of death among non-communicable diseases worldwide. Mortalities due to diabetes are associated with high cost, undesirable side effects, and less effectiveness of antidiabetic agents currently in clinical use. Therefore, this study investigated the antidiabetic and antihyperlipidemic potential of two flavonoids, 5,6,7,8-tetramethoxyflavone (1) and 5,6,7,4’-tetramethoxyflavone (2) in streptozotocin-nicotinamide induced diabetic Wistar rats. Oral acute toxicity test was conducted in male Wistar rats using the up and down method by following OECD Guideline 423. The doses, 5 and 50 mg/kg b.w were used for each flavonoid. No clinical signs of toxicity were observed for compound 1 at tested doses while compound 2 resulted in itching, reduced weight, and increased levels of creatinine. The LD50 values were established to be ≥ 50 mg/kg b.w for both compounds. In the evaluation of antidiabetic and antihyperlipidemic efficacy, diabetic Wistar rats were administered with 2.5, 5.0 and 7.5 mg/kg b.w for each compound. Compound 1 lowered the level of fasting blood glucose (FBG) significantly (p < 0.05) while compound 2 lowered FBG with no significant difference (p > 0.05) compared to the negative control. Both compounds did not avert weight loss but reduced the rate of weight loss in a dose-dependent manner. The levels of HDL-C increased with no significant difference (p > 0.05), while the levels of TC, TG, and LDL-C were reduced significantly (p < 0.05) for compound 1 compared to the negative control. Compound 2 reduced the levels of LDL-C, and increased the levels of TG significantly (p < 0.05) compared to the negative control. However, compound 2 resulted in inflation of the urinary bladder, and swelling of stomach, intestines, and testes of diabetic rats. Therefore, this study identifies and recommends 5,6,7,8-tetramethoxyflavone (1) as a promising antidiabetic and antihyperlipidemic agent.
Read full abstract